COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?

Am J Ophthalmol. 2020 Aug:216:A1-A2. doi: 10.1016/j.ajo.2020.03.029. Epub 2020 May 8.

Author

Michael F Marmor¹

Affiliation

¹ Department of Ophthalmology and Byers Eye Institute, Stanford University School of Medicine, Palo Alto, California. Electronic address: marmor@stanford.edu.

No abstract available

Publication types

Editorial

MeSH terms

Antirheumatic Agents / administration & dosage
Antirheumatic Agents / toxicity*
Antiviral Agents / administration & dosage
Antiviral Agents / toxicity
Betacoronavirus / drug effects*
COVID-19
China / epidemiology
Chloroquine / administration & dosage
Chloroquine / toxicity
Clinical Trials as Topic
Coronavirus Infections / drug therapy*
Coronavirus Infections / epidemiology
Humans
Hydroxychloroquine / administration & dosage
Hydroxychloroquine / toxicity*
Pandemics
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / epidemiology
Retina / drug effects*
Retina / pathology
Retinal Diseases / chemically induced*
Retinal Diseases / diagnosis
SARS-CoV-2

Substances

Antirheumatic Agents
Antiviral Agents
Hydroxychloroquine
Chloroquine